This podcast explores the best practices in molecular testing and targeted therapy for HR+/HER2- metastatic breast cancer.
Dr Rena Callahan and Dr Roberto Salgado discuss key biomarkers, testing methods, and clinical decision-making, offering expert insights on how to optimise precision medicine.
Topics include liquid vs. tumour biopsy, single gene vs. broad panel testing, and regional differences in testing practices.
Tune in for a practical, expert-led discussion on how molecular testing can guide personalised treatment and improve patient outcomes.
Key clinical takeaways:
You can also watch a video of the experts in conversation and download the accompanying transcript on our website: https://cor2ed.com/precision-oncology-connect/programmes/molecular-testing-targeted-therapy-metastatic-breast-cancer/?media=0
Or watch on YouTube: https://www.youtube.com/watch?v=CTnXmh1oDwQ
Follow us on social media:
LinkedIn: https://www.linkedin.com/company/ntrk-connect/
X: https://x.com/PresOnc_Connect
This content is intended for healthcare professionals only.
The medical experts in this podcast are expressing their own views and not those of COR2ED, Supporters or their institution. This podcast is supported by an Independent Education Grant from Thermo Fisher Scientific.
This podcast is developed by cor2ed.com
Published March 2025
Subscribe to this channel to stay up to date with new Independent Education programmes as they’re released.
Dr Neal Shore, Uro-Oncologist and Chief Medical Officer for Genesis Care and Urology and Surgical Oncology in the United States and Dr Elena Castro,...
In this first episode of a two-part podcast series focusing on neuroendocrine tumours (NETs), gastroenterologist Dr Mohid S Khan and NET patient Sally Jenkins...
Metastatic pancreatic ductal adenocarcinoma (mPDAC) is notoriously aggressive with a poor prognosis. It is often diagnosed late, and by this time, surgery is usually...